91 related articles for article (PubMed ID: 31076447)
21. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
22. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
23. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
[TBL] [Abstract][Full Text] [Related]
25. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
Salit RB; Deeg HJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
[TBL] [Abstract][Full Text] [Related]
26. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
27. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.
Kröger N; Panagiota V; Badbaran A; Zabelina T; Triviai I; Araujo Cruz MM; Shahswar R; Ayuk F; Gehlhaar M; Wolschke C; Bollin R; Walter C; Dugas M; Wiehlmann L; Lehmann U; Koenecke C; Chaturvedi A; Alchalby H; Stadler M; Eder M; Christopeit M; Göhring G; Koenigsmann M; Schlegelberger B; Kreipe HH; Ganser A; Stocking C; Fehse B; Thol F; Heuser M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1095-1101. PubMed ID: 28389256
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.
Guglielmelli P; Rotunno G; Pacilli A; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pieri L; Fjerza R; Pietra D; Cilloni D; Sant'Antonio E; Salmoiraghi S; Passamonti F; Rambaldi A; Barosi G; Barbui T; Cazzola M; Vannucchi AM
Am J Hematol; 2016 Sep; 91(9):918-22. PubMed ID: 27264006
[TBL] [Abstract][Full Text] [Related]
30. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
Tefferi A; Nicolosi M; Mudireddy M; Lasho TL; Gangat N; Begna KH; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 May; 32(5):1189-1199. PubMed ID: 29472717
[TBL] [Abstract][Full Text] [Related]
31. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
32. ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
Valikhani A; Poopak B; Ferdowsi S; Azizi Tabesh G; Ghaffari SH; Saraf Kazeruoni E; Rezaei N; Farshchi A; Amirizadeh N
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e41-e47. PubMed ID: 27640403
[TBL] [Abstract][Full Text] [Related]
33. The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis.
Li B; Xu Z; Li Y; Peter Gale R; Song Z; Ai X; Qin T; Zhang Y; Zhang P; Huang G; Xiao Z
Am J Hematol; 2016 Jul; 91(7):E320-1. PubMed ID: 27059877
[No Abstract] [Full Text] [Related]
34. Prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract][Full Text] [Related]
35. ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.
Shivarov V; Gueorguieva R; Ivanova M; Tiu RV
Leuk Lymphoma; 2015 Jun; 56(6):1881-3. PubMed ID: 25308295
[No Abstract] [Full Text] [Related]
36. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
[TBL] [Abstract][Full Text] [Related]
37. TP53 mutations and polymorphisms in primary myelofibrosis.
Raza S; Viswanatha D; Frederick L; Lasho T; Finke C; Knudson R; Ketterling R; Pardanani A; Tefferi A
Am J Hematol; 2012 Feb; 87(2):204-6. PubMed ID: 22052707
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
39. ASXL1 mutations are frequent in de novo AML with trisomy 8 and confer an unfavorable prognosis.
Zong X; Yao H; Wen L; Ma L; Wang Q; Yang Z; Zhang T; Chen S; Depei W
Leuk Lymphoma; 2017 Jan; 58(1):204-206. PubMed ID: 27736271
[No Abstract] [Full Text] [Related]
40. Comparison of JAK2
Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
